Retrophin

What Retrophin does

Retrophin (now operating as Travere Therapeutics, Inc.) is a publicly traded biopharmaceutical company headquartered in San Diego, California, that focuses on developing and commercializing therapies for people living with rare diseases. Founded in 2012 and rebranded from its original Retrophin identity to Travere Therapeutics in 2022, the company is listed on NASDAQ (evidenced by Nasdaq Listing Rule 5635(c)(4) disclosures) and operates across four therapeutic areas: IgA Nephropathy (IgAN), Focal Segmental Glomerulosclerosis (FSGS), Classical Homocystinuria (HCU), and Cystinuria. The company has a stated headcount of 101-250 employees and structures its go-to-market around direct physician and patient outreach, patient advocacy partnerships, and specialty care channels in rare kidney disease communities.

The commercial portfolio centers on FILSPARI (sparsentan), an endothelin angiotensin receptor antagonist that has received full U.S. FDA approval for both FSGS — where it is the first and only approved medicine — and IgA Nephropathy. Travere also markets Thiola and Thiola EC for cystinuria (registered trademarks of Mission Pharmacal Company, held under license or distribution arrangement). The development pipeline is anchored by Pegtibatinase, an investigational enzyme replacement therapy for Classical Homocystinuria, expanding the proprietary science base into rare metabolic disease. Filspari, Total Care Hub, and Travere TotalCare are registered trademarks of Travere Therapeutics.

Revenue is generated through prescription pharmaceutical product sales of FDA-approved therapies (FILSPARI; Thiola / Thiola EC) distributed within the United States via specialty pharmacy channels to healthcare providers and patients. Patient access is supported by branded programs — Total Care Hub and Travere TotalCare — providing adherence and care-coordination services. The company engages the market through a multi-channel model: organic social (Facebook, Instagram, LinkedIn, X, YouTube), content marketing through the Rare Life patient-story program, medical affairs engagement including presentations at major scientific congresses such as the European Renal Association, and earned media / investor relations. Specific drug pricing is not publicly disclosed and is accessed via healthcare providers and specialty pharmacies using standard insurance coverage mechanics.

Name

Retrophin

Legal name

Travere Therapeutics, Inc.

Website

https://Retrophin.com

Company type

Public

Founded year

2012

Operating status

Operating

Headcount range

101–250 employees

Short description

Travere Therapeutics (formerly Retrophin) is a publicly traded, San Diego-based biopharmaceutical company developing and commercializing FDA-approved therapies for rare kidney and metabolic diseases including FSGS, IgA Nephropathy, and cystinuria.

Ownership category

akta.pro rank

Product category

Rare Disease Specialty Pharmaceuticals

NAICS

Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Rare Renal & Nephrology Disorder Therapies (HLAIAIAI)

akta.pro secondary industries

Nephrology & Urology Specialty Pharmaceuticals (HLAIACAH), Nephrology & Urology Pharmaceuticals (HLAIAAAM), Genetic & Rare Kidney Disease Clinics (HLAKAHAO)

Keywords

• Rare disease therapeutics
• Kidney disease treatments
• Orphan drug development
• Specialty pharmaceuticals
• Enzyme replacement therapy

Headquarters

HQ city

San Diego

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B and B2C

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Marketing or Sales, Operations, Supply Chain

Revenue model

1. Pharmaceutical Product Sales: Revenue generated from the sale of FDA-approved prescription medications including FILSPARI (sparsentan) for FSGS and IgAN, and Thiola/Thiola EC for cystinuria. The company develops and commercializes therapies for rare kidney diseases and metabolic disorders.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

Retrophin (operating as Travere Therapeutics) develops and commercializes FDA-approved prescription therapies for rare kidney diseases and rare metabolic disorders. Core commercial products include FILSPARI (sparsentan) for Focal Segmental Glomerulosclerosis (FSGS) and IgA Nephropathy (IgAN), and Thiola/Thiola EC for cystinuria. The company's pipeline includes Pegtibatinase, an investigational enzyme replacement therapy for Classical Homocystinuria (HCU).

Product overview

Travere Therapeutics (formerly Retrophin) is a patient-centered biopharmaceutical company focused on developing therapies for rare kidney diseases. The company's product portfolio includes FILSPARI (sparsentan), an FDA-approved treatment for Focal Segmental Glomerulosclerosis (FSGS) and IgA Nephropathy (IgAN), and Thiola/Thiola EC for cystinuria. The pipeline includes Pegtibatinase for Classical Homocystinuria (HCU). The company operates across four main therapeutic areas: IgA Nephropathy, FSGS, Classical Homocystinuria, and Cystinuria.

Differentiator

Problem solved

Functional benefit

Brands

• Total Care Hub: Registered trademark; patient support and care program
• Travere TotalCare
• Filspari
• Thiola

Products and services

• FILSPARI (sparsentan) FILSPARI (sparsentan) is an FDA-approved endothelin angiotensin receptor antagonist indicated for the treatment of Focal Segmental Glomerulosclerosis (FSGS) and IgA Nephropathy (IgAN). It is the first and only approved medicine for FSGS, targeting patients with rare kidney diseases who have limited therapeutic options.
• Thiola Thiola is a registered trademark prescription medication for the treatment of cystinuria, a rare metabolic disorder. It is licensed or acquired from Mission Pharmacal Company.
• Thiola EC Thiola EC is an enteric-coated formulation of the cystinuria treatment medication Thiola, providing an alternative dosing form for patients with cystinuria. Thiola EC is a registered trademark of Mission Pharmacal Company.
• Pegtibatinase Pegtibatinase is an investigational enzyme replacement therapy in clinical development for the treatment of Classical Homocystinuria (HCU), a rare inherited metabolic disorder.

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

One partnership is on record.

• European Renal Association (ERA)minorStrategic or Co-development Partner · 4 June 2026Travere Therapeutics presented long-term open-label extension data from the Phase 3 DUPLEX Study at the 63rd European Renal Association (ERA) 2026 Congress, showcasing clinical trial results for their therapeutic candidates.

Scale indicators1 record

Recent moves6 records

Expansion highlights5 records

Direct peers

• Calliditas Therapeutics: Calliditas developed Tarpeyo, an FDA-approved targeted-release budesonide for IgA Nephropathy, directly competing with Travere's FILSPARI in the same rare kidney indication and overlapping specialty nephrology customer base.
• Chinook Therapeutics (Novartis): Pre-acquisition by Novartis, Chinook was a clinical-stage rare kidney disease company developing therapies for IgAN and other rare nephropathies, making it a direct comparator in rare kidney pipeline strategy and indication focus.
• Vera Therapeutics: Vera is developing atacicept for IgA Nephropathy, positioning it as a direct competitor to FILSPARI in IgAN with a similar specialty nephrology commercial target and patient advocacy model.
• Reata Pharmaceuticals: Reata developed and commercialized bardoxolone methyl for rare forms of CKD, making it a comparable rare kidney disease biopharma with overlapping nephrology prescribers and similar regulatory pathway focus.
• Travere Therapeutics (self-reference): The subject company itself; included as a reference point given the firmographic name (Retrophin) and operational entity (Travere Therapeutics) refer to the same organization, useful for historical comparisons.

Broad incumbents

• Otsuka Pharmaceutical: Otsuka markets tolvaptan for ADPKD, a rare kidney disease, and operates a broad rare disease and specialty pharma portfolio that overlaps with Travere's nephrology focus and specialty pharmacy distribution model.
• Alexion / AstraZeneca Rare Disease: Alexion is a global rare disease leader with complement-mediated kidney therapies (e.g., Soliris/Ultomiris in aHUS) and overlapping rare disease patient advocacy and specialty distribution infrastructure.
• BioMarin Pharmaceutical: BioMarin is an established rare disease biopharma with a multi-indication orphan drug portfolio and a similar specialty distribution and patient access model relevant to Travere's commercial approach.
• Vertex Pharmaceuticals: Vertex is expanding from its rare disease CF franchise into additional rare and specialty indications (including nephrology-adjacent assets via Alpine acquisition), making it a comparable scaling rare disease biopharma with similar capital markets profile.
• Ultragenyx Pharmaceutical: Ultragenyx is a rare and ultra-rare disease biopharma with a multi-asset pipeline and similar specialty distribution approach; HCU-adjacent metabolic disease portfolio makes it thematically comparable to Travere's HCU ambition.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/travererare
• YouTubeyoutube.com/@travere_rare
• Facebookfacebook.com/TravereRare
• LinkedInlinkedin.com/company/travererare
• Instagraminstagram.com/travererare

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Retrophin